Sara B Fournier1, David A Donley, Daniel E Bonner, Evan Devallance, I Mark Olfert, Paul D Chantler. 1. 1Department of Human Performance and Applied Sciences, Division of Exercise Physiology, School of Medicine, West Virginia University, Morgantown, WV; and 2Center for Cardiovascular and Respiratory Sciences, School of Medicine, West Virginia University, Morgantown, WV.
Abstract
PURPOSE: The metabolic syndrome (MetS) is associated with threefold increased risk of cardiovascular (CV) morbidity and mortality, which is partly due to a blunted CV reserve capacity, reflected by a reduced peak exercise left ventricular (LV) contractility and aerobic capacity and a blunted peak arterial-ventricular coupling. To date, no study has examined whether aerobic exercise training in MetS can reverse peak exercise CV dysfunction. Furthermore, examining how exercise training alters CV function in a group of individuals with MetS before the development of diabetes and/or overt CV disease can provide insights into whether some of the pathophysiological CV changes can be delayed/reversed, lowering their CV risk. The objective of this study was to examine the effects of 8 wk of aerobic exercise training in individuals with MetS on resting and peak exercise CV function. METHODS: Twenty participants with MetS underwent either 8 wk of aerobic exercise training (MetS-ExT, n = 10) or remained sedentary (MetS-NonT, n = 10) during this period. Resting and peak exercise CV function was characterized using Doppler echocardiography and gas exchange. RESULTS: Exercise training did not alter resting LV diastolic or systolic function and arterial-ventricular coupling in MetS. In contrast, at peak exercise, an increase in LV contractility (40%, P < 0.01), cardiac output (28%, P < 0.05), and aerobic capacity (20%, P < 0.01), but a reduction in vascular resistance (30%, P < 0.05) and arterial-ventricular coupling (27%, P < 0.01), were noted in the MetS-ExT but not in the MetS-NonT group. Furthermore, an improvement in lifetime risk score was also noted in the MetS-ExT group. CONCLUSIONS: These findings have clinical importance because they provide insight that some of the pathophysiological changes associated with MetS can be improved and can lower the risk of CV disease.
PURPOSE: The metabolic syndrome (MetS) is associated with threefold increased risk of cardiovascular (CV) morbidity and mortality, which is partly due to a blunted CV reserve capacity, reflected by a reduced peak exercise left ventricular (LV) contractility and aerobic capacity and a blunted peak arterial-ventricular coupling. To date, no study has examined whether aerobic exercise training in MetS can reverse peak exercise CV dysfunction. Furthermore, examining how exercise training alters CV function in a group of individuals with MetS before the development of diabetes and/or overt CV disease can provide insights into whether some of the pathophysiological CV changes can be delayed/reversed, lowering their CV risk. The objective of this study was to examine the effects of 8 wk of aerobic exercise training in individuals with MetS on resting and peak exercise CV function. METHODS: Twenty participants with MetS underwent either 8 wk of aerobic exercise training (MetS-ExT, n = 10) or remained sedentary (MetS-NonT, n = 10) during this period. Resting and peak exercise CV function was characterized using Doppler echocardiography and gas exchange. RESULTS: Exercise training did not alter resting LV diastolic or systolic function and arterial-ventricular coupling in MetS. In contrast, at peak exercise, an increase in LV contractility (40%, P < 0.01), cardiac output (28%, P < 0.05), and aerobic capacity (20%, P < 0.01), but a reduction in vascular resistance (30%, P < 0.05) and arterial-ventricular coupling (27%, P < 0.01), were noted in the MetS-ExT but not in the MetS-NonT group. Furthermore, an improvement in lifetime risk score was also noted in the MetS-ExT group. CONCLUSIONS: These findings have clinical importance because they provide insight that some of the pathophysiological changes associated with MetS can be improved and can lower the risk of CV disease.
Authors: Jarett D Berry; Alan Dyer; Xuan Cai; Daniel B Garside; Hongyan Ning; Avis Thomas; Philip Greenland; Linda Van Horn; Russell P Tracy; Donald M Lloyd-Jones Journal: N Engl J Med Date: 2012-01-26 Impact factor: 91.245
Authors: F H J van Tienen; S F E Praet; H M de Feyter; N M van den Broek; P J Lindsey; K G C Schoonderwoerd; I F M de Coo; K Nicolay; J J Prompers; H J M Smeets; L J C van Loon Journal: J Clin Endocrinol Metab Date: 2012-07-16 Impact factor: 5.958
Authors: Nora E Straznicky; Mariee T Grima; Carolina I Sari; Sofie Karapanagiotidis; Chiew Wong; Nina Eikelis; Katrina L Richards; Geraldine Lee; Paul J Nestel; John B Dixon; Gavin W Lambert; Markus P Schlaich; Elisabeth A Lambert Journal: J Clin Endocrinol Metab Date: 2012-12-27 Impact factor: 5.958
Authors: Paul S Bhella; Anand Prasad; Katja Heinicke; Jeff L Hastings; Armin Arbab-Zadeh; Beverley Adams-Huet; Eric L Pacini; Shigeki Shibata; M Dean Palmer; Bradley R Newcomer; Benjamin D Levine Journal: Eur J Heart Fail Date: 2011-10-05 Impact factor: 15.534
Authors: C A Fahs; L M Rossow; H Yan; S M Ranadive; S Agiovlasitis; K R Wilund; T Baynard; B Fernhall Journal: J Hum Hypertens Date: 2013-02-21 Impact factor: 3.012
Authors: Sara B Fournier; Brian L Reger; David A Donley; Daniel E Bonner; Bradford E Warden; Wissam Gharib; Conard F Failinger; Melissa D Olfert; Jefferson C Frisbee; I Mark Olfert; Paul D Chantler Journal: Exp Physiol Date: 2013-09-13 Impact factor: 2.969
Authors: E DeVallance; S Fournier; K Lemaster; C Moore; S Asano; D Bonner; D Donley; I M Olfert; P D Chantler Journal: Eur J Appl Physiol Date: 2016-03-03 Impact factor: 3.078